Literature DB >> 29063814

The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy.

Paula Province Warren1, E Martina Bebin1, L Burt Nabors1, Jerzy P Szaflarski1.   

Abstract

Epilepsy, commonly encountered by patients with brain tumors, is often refractory to standard therapies. Our aim was to examine the safety and efficacy of pharmaceutical grade cannabidiol (CBD; Epidiolex; Greenwich Biosciences) in those patients with epilepsy with concomitant tumors enrolled in The University of Alabama at Birmingham CBD Program (NCT02700412 and NCT02695537). Of the three patients with refractory seizures and a history of a primary brain tumor, two had improvement in seizure frequency and all three had improvement in seizure severity. These pilot results suggest that CBD should be further studied for the treatment of brain tumor-related epilepsy.

Entities:  

Keywords:  Brain tumor; CBD; cannabidiol; epilepsy; tumoral epilepsy

Mesh：

Substances：

Year:  2017        PMID： 29063814     DOI： 10.1080/13554794.2017.1391294

Source DB:  PubMed          Journal:  Neurocase        ISSN： 1355-4794            Impact factor:   0.881


  8 in total

Review 1.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

2.  Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450.

Authors:  Sumit Bansal; Neha Maharao; Mary F Paine; Jashvant D Unadkat
Journal:  Drug Metab Dispos       Date:  2020-06-25       Impact factor: 3.922

Review 3.  Cannabis, a Miracle Drug with Polyvalent Therapeutic Utility: Preclinical and Clinical-Based Evidence.

Authors:  Rishabh Verma; Farazul Hoda; Mawrah Arshad; Asif Iqubal; Ali Nasir Siddiqui; Mohammad Ahmed Khan; Syed Ehtaishamul Haque; Mohd Akhtar; Abul Kalam Najmi
Journal:  Med Cannabis Cannabinoids       Date:  2021-05-21

Review 4.  Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Authors:  Dinesh Upadhya; Olagide W Castro; Raghavendra Upadhya; Ashok K Shetty
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

5.  A systematic review of cannabidiol dosing in clinical populations.

Authors:  S A Millar; N L Stone; Z D Bellman; A S Yates; T J England; S E O'Sullivan
Journal:  Br J Clin Pharmacol       Date:  2019-07-19       Impact factor: 4.335

Review 6.  The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology.

Authors:  Clara Andradas; Alexandra Truong; Jacob Byrne; Raelene Endersby
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

7.  Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.

Authors:  Simona Lattanzi; Eugen Trinka; Pasquale Striano; Chiara Rocchi; Sergio Salvemini; Mauro Silvestrini; Francesco Brigo
Journal:  CNS Drugs       Date:  2021-03-22       Impact factor: 5.749

Review 8.  Is cannabidiol a drug acting on unconventional targets to control drug-resistant epilepsy?

Authors:  Luisa Rocha; Christian Lizette Frías-Soria; José G Ortiz; Jerónimo Auzmendi; Alberto Lazarowski
Journal:  Epilepsia Open       Date:  2020-01-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.